For AI assistants & researchers — machine-readable summary of this page
What this page is: Delvantic's full research page for AbbVie Inc. (ABBV) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.
Our current read (analysis of 2026-08-23): Designation Low · Gem Score -29 (−100…+100 Quality+Value blend) · Quality 23 · Value -71 · Sentiment 24 (timing only, not weighted) · Composite fair value $177.31 vs $257.41 at analysis
Page map (sections in order; each card carries a stable
reference-name attribute you can cite):
profile-header/price-overview— company profile, live quote, market capextended-analysis— the core: three AI lens reads with findings, scores, and the analyst memofuture-predictions— our forward price-band predictionsmarket-narrative/ai-findings/gpt-critique— narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)- Members-only sections (render as login gates for anonymous readers):
price-history,income-trend,key-metrics,financials(statement tables),insider-trading. The analysis above is public; the raw data tables require a free account.
More for machine readers: site briefing at
/llms.txt ·
any ticker resolves at delvantic.com/stock/TICKER ·
raw inputs are public-company filings and market data (via licensed data feeds);
every model, score, lens read, and prediction on this page is Delvantic's own analysis.
AbbVie Inc.
ABBV NYSEAbbVie Inc. is a research-based biopharmaceutical company that discovers, develops, manufactures, and commercializes innovative medicines and therapies worldwide. The company maintains a strong focus on immunology, offering treatments like Humira, Skyrizi, and Rinvoq for autoimmune and inflammatory conditions in rheumatology, gastroenterology, dermatology, and related areas. In oncology, it provides therapies such as Imbruvica, Venclexta, Elahere, Epkinly, and Emrelis targeting blood cancers, lymphoma, and lung cancer. AbbVie Inc. also addresses virology with Mavyret for hepatitis C, neuroscience for neurological disorders like Parkinson's, and additional areas including metabolic diseases, cystic fibrosis complications, endometriosis pain, irritable bowel syndrome, chronic constipation, and pancreatic enzyme therapy with Creon, alongside aesthetics products like Botox and Linzess/Constella. Founded in 2013 and headquartered in North Chicago, Illinois, AbbVie Inc. plays a vital role in the healthcare sector by delivering solutions for complex, chronic, and serious health conditions.
Price Overview
Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): 2.36
Total Equity: -$3.23B
Shares: 1,773,000,000
Total Debt: $67.00B
Cash: $5.23B
EBITDA: $15.84B
Total Debt: $67.00B
Cash: $5.23B
Revenue: $61.16B
Revenue: $61.16B
Revenue: $61.16B
Total Equity: -$3.23B
Tax Rate: 35.8%
Equity: -$3.23B
Total Debt: $67.00B
Cash: $5.23B
Current Liabilities: $43.29B
Long-Term Debt: $64.50B
Total Debt: $67.00B
Total Equity: -$3.23B
Shares: 1,773,000,000
Shares: 1,773,000,000
CapEx: -$1.21B
Shares: 1,773,000,000
Stock Price: $258.39
Net Income: $4.23B
Industry Benchmarks
Income Statement (Annual)
Last updated: Jul 29, 2026 9:33pm (24d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $56.2B | $58.1B | $54.3B | $56.3B | $61.2B |
| Cost of Revenue | $17.4B | $17.4B | $20.4B | $16.9B | $18.2B |
| Gross Profit | $38.8B | $40.6B | $33.9B | $39.4B | $43.0B |
| Operating Expenses | $20.8B | $22.5B | $21.1B | $30.3B | $27.9B |
| Operating Income | $17.9B | $18.1B | $12.8B | $9.1B | $15.1B |
| Net Income | $11.5B | $11.8B | $4.9B | $4.3B | $4.2B |
| EBITDA | $18.7B | $18.9B | $13.5B | $9.9B | $15.8B |
| EPS | $6.48 | $6.65 | $2.73 | $2.40 | $2.37 |
| EPS (Diluted) | $6.45 | $6.63 | $2.72 | $2.39 | $2.36 |
Balance Sheet (Annual)
Last updated: Jul 29, 2026 9:33pm (24d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $9.7B | $9.2B | $12.8B | $5.5B | $5.2B |
| Total Current Assets | $27.9B | $28.5B | $33.0B | $25.6B | $29.1B |
| Total Assets | $146.5B | $138.8B | $134.7B | $135.2B | $134.0B |
| Current Liabilities | $35.2B | $29.5B | $37.8B | $38.7B | $43.3B |
| Long-Term Debt | $76.0B | $63.1B | $59.2B | $66.8B | $64.5B |
| Total Liabilities | $131.1B | $121.5B | $124.3B | $131.8B | $137.2B |
| Total Equity | $15.4B | $17.3B | $10.4B | $3.4B | -$3.2B |
| Retained Earnings | $3.1B | $4.8B | -$1.0B | -$7.9B | -$15.5B |
Cash Flow (Annual)
Last updated: Jul 29, 2026 9:33pm (24d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $22.8B | $24.9B | $22.8B | $18.8B | $19.0B |
| Capital Expenditure | -$787.0M | -$695.0M | -$777.0M | -$974.0M | -$1.2B |
| Free Cash Flow | $22.0B | $24.2B | $22.1B | $17.8B | $17.8B |
| Acquisitions (net) | -$525.0M | -$255.0M | $0 | -$17.5B | -$204.0M |
| Net Debt Issued / (Repaid) | -$8.4B | -$12.4B | -$4.1B | $12.4B | $2.0B |
| Dividends Paid | -$9.3B | -$10.0B | -$10.5B | -$11.0B | -$11.7B |
| Stock Buybacks | -$934.0M | -$1.5B | -$2.0B | -$1.7B | -$980.0M |
| Net Change in Cash | $1.3B | -$545.0M | $3.6B | -$7.3B | -$295.0M |
Growth Trends (YoY %)
Last updated: Jul 29, 2026 9:33pm (24d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +3.3% | -6.4% | +3.7% | +8.6% |
| Gross Profit Growth | +4.9% | -16.6% | +16.3% | +8.9% |
| Operating Income Growth | +1.1% | -29.6% | -28.4% | +65.0% |
| Net Income Growth | +2.5% | -58.9% | -12.0% | -1.2% |
| EBITDA Growth | +0.9% | -28.5% | -26.7% | +60.0% |
Dividend History (Last 20)
Last updated: Jul 30, 2026 6:15pm (24d ago)| Date | Dividend | Declaration | Record | Payment |
|---|---|---|---|---|
| 2026-07-15 | $1.73 | — | — | — |
| 2026-04-15 | $1.73 | — | — | — |
| 2026-01-16 | $1.73 | — | — | — |
| 2025-10-15 | $1.64 | — | — | — |
| 2025-07-15 | $1.64 | — | — | — |
| 2025-04-15 | $1.64 | — | — | — |
| 2025-01-15 | $1.64 | — | — | — |
| 2024-10-15 | $1.55 | — | — | — |
| 2024-07-15 | $1.55 | — | — | — |
| 2024-04-12 | $1.55 | — | — | — |
| 2024-01-12 | $1.55 | — | — | — |
| 2023-10-12 | $1.48 | — | — | — |
| 2023-07-13 | $1.48 | — | — | — |
| 2023-04-13 | $1.48 | — | — | — |
| 2023-01-12 | $1.48 | — | — | — |
| 2022-10-13 | $1.41 | — | — | — |
| 2022-07-14 | $1.41 | — | — | — |
| 2022-04-13 | $1.41 | — | — | — |
| 2022-01-13 | $1.41 | — | — | — |
| 2021-10-14 | $1.30 | — | — | — |
Deep Analysis
Risk : Reward — if the last quarter repeats
Live · as of 2026-08-20 23:30Even the bull case prices 17% below today — the ratio here measures the model-vs-market gap, not payoff odds. Another quarter like the worst recent one costs 88%.
| Case | Growth | Margin | Fair value | vs price ($257.41) |
|---|---|---|---|---|
| Bull — recovery | +14% | 33.2% | $213.53 | -17% |
| Base — stabilizes | +9% | 28.9% | $160.68 | -38% |
| Bear — keeps slipping | +5% | 24.6% | $117.92 | -54% |
| Stress — last quarter repeats | +9% | 4.9% | $31.36 | -88% |
Narrative Economics
market-narrative step).
Claude Reading
The raw quarterly tape tells a messier story than "successfully navigating the cliff." Q1 2026 revenue of $15.0B is down sequentially from $16.62B in Q4 2025, with net margin collapsing to 4.6% — and Q3 2025 net margin was 1.2% on $15.78B revenue ($186M NI). Full-year 2025 NI of $4.23B on $61.16B revenue (6.9% net margin) is roughly a third of 2021-2022 levels ($11.5-11.8B NI on ~$56-58B rev). Revenue is growing (+8.6% YoY recent, 6.1% CAGR) but earnings quality is deteriorating — operating margin has compressed from ~32% in 2021-22 to 24.6% in 2025, and net margin has cratered. The Skyrizi/Rinvoq ramp is real on the top line, but the bottom line suggests either heavy amortization from ImmunoGen/Cerevel deals, ongoing IPR&D charges, or genuine gross margin erosion — gross margin at 70.2% is still healthy, so the leakage is below the line. Balance sheet is genuinely ugly: $67B debt vs $5.2B cash, negative $3.2B equity, current ratio 0.67, payout ratio 275%. This is a company financing dividends with debt and FCF, not earnings.
The synthesis verdict of $158-159 fair value (-38% from $258) is directionally right but likely too harsh on the mechanics. At $17.8B FCF and a $465B market cap, that's ~26x P/FCF for a pharma with 6% top-line growth, a legitimate GLP-1-adjacent immunology franchise, and a dividend that consumes ~$11B/year. A more defensible fair value framework: put ABBV at 18-20x normalized FCF (roughly the sector for slower-growth large pharma with patent risk) = $320-355B market cap = $178-197/share. So I'd anchor fair value closer to $185-200, not $159 — the DCF is probably discounting terminal decline too aggressively given Skyrizi is tracking toward $20B+ peak sales alone. That still implies 25-30% downside from $258, so the "overvalued" call stands; I just think the magnitude is overstated.
The contrarian case worth taking seriously: Skyrizi + Rinvoq combined are on pace to exceed peak Humira revenue by 2027, and the IRA negotiation overhang on Rinvoq is 2026-2028, not immediate. If oncology (Elahere from ImmunoGen, emraclidine from Cerevel — wait, that one failed Phase II) delivers even one surprise, the depressed 2025-26 earnings become the trough and P/E normalizes to 20x on $8-10B NI = fair. The bear case that's underweighted in the models: emraclidine's failure in late 2024 was a $9B write-down event that markets seem to have forgiven too quickly, and the negative book equity from serial acquisitions means any further pipeline disappointment hits a company with no equity cushion and $67B of debt. The insider data is useless — all A-Awards, no open-market activity, no signal either way.
I partially agree with the synthesis: ABBV is overvalued, but $159 is too pessimistic and $258 is too optimistic. The narrative layer nails it — this is a bond-proxy trading on dividend durability, and with the 10Y where it is, the yield support argument is weaker than it was 18 months ago. The 2.6% dividend yield is not compelling compensation for a company with negative equity, decelerating quarterly revenue (Q1 26 down 10% sequentially), and a payout ratio above 100% of GAAP earnings. Market Forces' "neutral" call is too generous; the asymmetry here is clearly downside-skewed given IRA/JAK regulatory overhang on Rinvoq specifically. I'd want to see ABBV in the $190-210 range before it's interesting, and the catalyst path down is any of: Q2 2026 miss, biosimilar Skyrizi timeline acceleration, or FDA restriction on Rinvoq label. The catalyst up requires an oncology surprise the pipeline doesn't obviously contain.
GPT Reading
AbbVie looks expensive here because the income statement has not remotely caught up to the stock price. At $258, the company is valued at about $465 billion on $61.2 billion of 2025 revenue, or 7.6x sales, and the enterprise multiple is even richer at 8.6x revenue and 33.3x EBITDA. Those are not “mature pharma navigating a trough” numbers; those are premium-compounder numbers. Yet the actual reported earnings base is weak and volatile: 2025 net income was just $4.23 billion, down from $11.8 billion in 2022, and quarterly net margins over the last eight reported quarters have swung from -0.1% to 10.9%, with the latest quarter at only 4.6%. Even if some of that is acquisition amortization and other non-cash pharma accounting noise, the market is capitalizing AbbVie as if trough economics are temporary and a clean recovery is highly visible. I don’t think the reported data supports that confidence.
What does support the stock is cash generation, and it is real. Operating cash flow of $19.0 billion and free cash flow of $17.8 billion on just $1.2 billion of capex is excellent, and it explains why investors are willing to look through ugly GAAP EPS. But even on that friendlier lens, the valuation is not cheap: the stock trades around 26x FCF, which is rich for a large-cap pharma facing product concentration transitions, regulatory overhangs, and balance-sheet leverage. The balance sheet is not broken, but $67.0 billion of debt against only $5.2 billion of cash and negative equity of $3.2 billion removes some strategic flexibility. A current ratio of 0.67 is manageable for a company with recurring cash inflow, yet it reinforces that this is a levered cash-distribution story, not a pristine fortress. If free cash flow were already back above $20 billion and growing, I could justify a premium. At $17.8 billion FCF and still-lumpy earnings, I can’t justify paying this much.
The most important contradiction in the briefing is the “high-growth profitable” framing. This is neither. Revenue has grown from $56.2 billion in 2021 to $61.2 billion in 2025, a perfectly respectable but hardly explosive 6.1% CAGR, while earnings and free cash flow have both gone backward over that span. The latest annual revenue rebound from $56.3 billion to $61.2 billion is good, and the recent quarterly year-on-year growth of 8.6% suggests the post-Humira reset is not catastrophic. But if the business were truly through the patent cliff and re-accelerating cleanly, I would expect to see that in operating leverage and bottom-line normalization. Instead, operating income in 2025 was $15.1 billion, better than 2024’s $9.1 billion but still below 2022’s $18.1 billion, and net income remains stuck around $4-5 billion. The market is effectively paying today for a recovery that still has to be proven in the reported numbers.
The strongest case against my view is straightforward: GAAP materially understates AbbVie’s earning power, and cash flow is the truer metric. A smart bull would say 2024-2026 are transition years distorted by amortization and one-time items, while the actual franchise quality is visible in 70.2% gross margins, 24.7% operating margins, nearly $18 billion of FCF, and a revenue base that has already resumed growth despite the biggest patent cliff in big pharma. On that argument, a 2.6% dividend yield is not a warning sign but a sign of investor trust, and the debt is serviceable because the business throws off so much cash. I take that seriously. If one normalizes earnings meaningfully upward and assumes Skyrizi/Rinvoq-style replacement economics keep revenue climbing mid-single digits, then today’s multiple is less absurd than the 111x P/E suggests. My pushback is that even normalized, the stock still seems priced for a smooth, low-risk handoff. Large pharma transitions are rarely that linear, and AbbVie’s recent quarter-to-quarter profit volatility says the market is paying for certainty that the financials have not yet earned.
What would change my mind is not another “strong cash flow despite noise” quarter; AbbVie already has that. I would need to see sustained evidence that the revenue recovery converts into cleaner earnings power: at least two to three consecutive quarters with revenue above $15.5-$16.0 billion and net margin back consistently into the low-to-mid teens, plus annualized FCF tracking toward $20-$21 billion without leverage rising further. If that happened, the current price would look more like a justified premium on normalized cash earnings. Conversely, if revenue growth remains decent but net income stays stuck in the sub-$1 billion quarterly range, the stock should not hold a $465 billion valuation. For now, fair value looks much closer to the high-$100s than the mid-$250s.
Grok Reading
The raw numbers show a company that has partially cleared the Humira cliff on the top line but remains structurally impaired underneath. Revenue hit $61.16B in 2025, up 8.6% from $56.33B and finally above the 2022 peak of $58.05B, confirming Skyrizi and Rinvoq are carrying the immunology franchise. Operating income rebounded hard to $15.08B from the 2024 trough of $9.14B, and free cash flow of $17.82B on only $1.21B of capex is still formidable. Yet net income is stuck at $4.23B (6.9% margin) versus the $11B+ pre-cliff era, quarterly margins are lurching between 1.2% and 10.9%, and the trailing twelve months include a $695M print that underscores ongoing earnings noise. The balance sheet is the real tell: $67B of debt, $5.23B of cash, a current ratio of 0.67, and negative equity of –$3.23B. A 275% earnings payout ratio funding a 2.59% dividend yield is only sustainable because FCF covers it at roughly 67%; that is not a fortress, it is a leveraged cash-return machine running hot. At 111x earnings, 26x FCF, 33x EV/EBITDA and 7.6x sales, the market is capitalizing trough-to-mid-cycle recovery as if mid-teens operating margins and $20B+ FCF are already locked. The rule-based “high-growth profitable” tag is simply wrong—6% revenue CAGR and negative earnings CAGR do not qualify—and the $159 composite fair value from the models is directionally correct even if the precise anchor is debatable.
The cleanest bull counter is that FCF quality remains excellent, revenue has already reclaimed and exceeded the Humira peak, and operating margin has climbed back to 24.7% with further operating leverage available as the newer immunology assets scale and Allergan-related amortization rolls off. A skeptic of the overvalued call would note that 26x a depressed $17.8B FCF compresses quickly if the company reaches $22–25B of FCF by 2028 while holding a mid-20s operating margin; under that path the current $465B enterprise starts to look closer to fair on a normalized basis, and the dividend becomes an attractive bond proxy again. Negative equity is largely an accounting artifact of the Allergan deal and buybacks rather than imminent distress, given the cash generation. Those points have merit on a three-to-five-year view, but they require flawless execution on Rinvoq safety perception, continued biosimilar containment, and no major pipeline setbacks—precisely the perfection already discounted at $258.
I would reverse to neutral or better only if the next two reported quarters show operating margin sustainably above 28%, FCF run-rate clearly above $20B, and absolute debt reduction of at least $5–7B that begins repairing the equity account. Failure of Skyrizi/Rinvoq growth to offset residual Humira erosion, or any incremental JAK-class restriction, would confirm the downside.
Big-3 Panel — where each AI stands
Advanced Analysis Forensic deep-dive · separate lenses
AbbVie is a highly profitable, cash-generative franchise: 2025 revenue of $61.16B rebounded above the 2022 peak, gross margin sits at a stable 70.2%, and free cash flow of $17.82B remains enormous even after the Humira LOE cliff. Earnings quality looks pristine on the mechanical checks - OCF/NI of 3.54x, accruals at -10.5% of assets, Beneish M of -2.87 - suggesting reported profits are more than backed by cash. Share count has actually shrunk slightly (diluted CAGR -0.1%) and buybacks run 178% of SBC, so per-share value is being protected rather than eroded.
The soft spots are real. Net debt of roughly $62B against only $5.26B liquid cash makes the balance sheet a constraint - Altman Z at 2.57 sits in the grey zone. Operating margin collapsed from 31.9% (2021) to 16.2% (2024) before partially recovering to 24.6% (2025), and net income has more than halved from $11.84B (2022) to $4.23B (2025) even as revenue grew - implying heavy amortization/step-up charges and acquisition-related dilution of GAAP earnings, likely tied to Immunology transition spend and deals like Cerevel/ImmunoGen. FCF has also drifted down from $24.25B (2022) to $17.82B (2025).
Insider tape is uninformative - all A-Award grants, no open-market P or S in the window shown (the $10.7M of sales referenced sit outside this tape). Overall: a durable, well-run large-cap pharma with genuine post-LOE navigation risk and a levered capital structure, not a fortress.
Verify before trusting this (5)
- Composition of the $61B net debt - maturity ladder and fixed/floating mix
- Whether the OpM compression is primarily acquisition-related amortization (Allergan/Cerevel/ImmunoGen) vs underlying deterioration
- Skyrizi + Rinvoq combined run-rate revenue and growth vs Humira decline trajectory
- Pipeline concentration and next material LOE dates (aesthetics, oncology, neuroscience)
- Details of the $10.7M insider sales referenced in context - were they 10b5-1 or discretionary
The e2e composite pins fair value at $158 (signal-adjusted $159) against a $257 price - roughly 38% downside, or put differently, the market is paying about 1.6x the blended deserved value. The three methods bracket the answer: DCF at $239 (closest to price, assumes the Skyrizi/Rinvoq ramp fully offsets Humira erosion and beyond), EPV floor at $76 (current earnings power alone doesn't come close to justifying the price), anchored P/E at $54 (GAAP earnings are still depressed post-cliff, so this one is mechanically low and I'd discount it as a runaway low-side print). Even leaning generously on the DCF, you're paying ~8% above the most optimistic of the three anchors.
Verify before trusting this (5)
- Skyrizi + Rinvoq combined run-rate and 2025-2026 guidance vs Humira erosion pace
- Segment gross margin trajectory as biosimilar mix shifts
- Free cash flow coverage of the dividend post-cliff
- Any one-time IPR&D or acquisition charges distorting GAAP EPS anchor
- Debt paydown schedule and refi assumptions
The active narrative around ABBV is unusually supportive right now: a steady stream of 'Dividend King', 'cheaper than you think on forward earnings', 'still attractively valued at all-time highs' pieces is doing exactly what bullish narratives do, drip-feeding a bid into the name into Friday's Q2 print. Add fresh EU regulatory wins for Rinvoq and a consumer-facing Juvederm push, and the news tape is clean-to-positive with no visible narrative crack. Analyst tone in the coverage skews constructive despite the stock sitting at highs. On the macro side, the tape is neutral with VIX 17 and the market only 2.3% off highs - not a risk-off event - and even if it were, ABBV's 0.28 beta and defensive pharma profile mean the macro headwind (10y 4.67%, rich market PE) lands very softly here. Bond-proxy pharma with a 3.5% yield actually benefits when investors get nervous about high-multiple growth names, which is the subtle rotation undertone. Net: moderate but real upward pressure from narrative and flow, with earnings Friday as the single binary that could flip it.
Verify before trusting this (4)
- Friday Q2 print: Humira erosion pace and Skyrizi/Rinvoq guide - a beat/raise extends the tailwind, a miss cracks the compounder story
- Whether the 'priced for perfection / DCF-rich' framing gains traction in sell-side notes post-print
- Rotation flow: if VIX pushes higher, does defensive pharma keep catching bids or does the whole tape sell off
- Any biosimilar competitive data or pricing headline that would harden the bear narrative
This lens hasn't been run for this ticker yet.
When we made this prediction on Jul 31, 2026, ABBV was $257.41. We expect it to be $244.00 by Jan 2027, and we consider it great value under $210.00. This is an early model (v0.6.0) — the direction is more reliable than the exact price. Made Jul 31, 2026.
Blue is our prediction, starting the day we made it. Grey is a slower route to the same place — the same destination, taking longer. Black is the actual price, so you can see how we are doing.